- Home
- SLS vs MPLT Comparison
SLS vs MPLT Comparison
Compare SLS & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLS | MPLT |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 706.7M | 811.3M |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | SLS | MPLT |
|---|---|---|
| Price | $4.90 | $26.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $10.00 | ★ $32.67 |
| AVG Volume (30 Days) | ★ 5.6M | 240.6K |
| Earning Date | 05-12-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $67.40 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.27 | $12.24 |
| 52 Week High | $6.14 | $30.28 |
Technical Indicators
Market Signals| Indicator | SLS | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 52.15 | 70.10 |
| Support Level | $4.70 | $16.19 |
| Resistance Level | $5.18 | N/A |
| Average True Range (ATR) | 0.29 | 2.09 |
| MACD | 0.03 | 0.57 |
| Stochastic Oscillator | 75.61 | 76.48 |
Price Performance
Historical ComparisonAbout SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
About MPLT MapLight Therapeutics Inc.
MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.